Novo Nordisk target cut by Deutsche Bank despite long-term optimism

5 days ago 4

Proactive

Wed, February 11, 2026 astatine 7:45 AM CST 1 min read

Novo Nordisk people chopped by Deutsche Bank contempt semipermanent optimism

Deutsche Bank has chopped its terms people for Novo Nordisk (NYSE:NVO) by 16% to DKK400 pursuing a turbulent week for the Danish pharmaceutical group, citing gross headwinds, absorption uncertainty and objective proceedings risks.

Emmanuel Papadakis, equity expert astatine Deutsche Bank, described the play station fourth-quarter results arsenic “the champion of times, the worst of times”, reflecting a premix of beardown merchandise imaginable and acute concern volatility.

He warned of a “double-digit gross decline” successful the existent year, but said the banal was backmost to trading astatine a “mid-teens price-to-earnings ratio”, supported by the motorboat of its oral obesity attraction and imaginable request betterment successful the 2nd half.

“We are clear-eyed that the volatility is pugnacious to stomach, the absorption concern remains fluid, concern visibility is constricted and determination remains a wide downside scenario,” Papadakis said, adding that information from trials of CagriSema, a cardinal obesity attraction candidate, would beryllium critical.

Despite the people cut, Deutsche Bank reiterated its 'buy' rating.

In mid-afternoon, the shares were disconnected 2.4% to DKK307.55.